Optimizing Outcomes after Heart Transplantation in Patients with Cardiac Amyloidosis - A Single Center Analysis of 48 Patients in 2 Eras

The prognosis of symptomatic cardiac amyloidosis - either of light chain (AL) or transthyretin (ATTR) type - is poor. Heart transplantation (HTX) might improve prognosis, but, previous reports suggested unfavorable survival after HTX in this population compared to HTX recipients with other indications as ischemic or dilative heart disease. Here, we analyzed our single center experience regarding HTX for cardiac amyloidosis.

Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: M.M. Kreusser, A.V. Kristen, S.O. Sch önland, P. Blum, B. Schmack, A. Ruhparwar, U. Hegenbart, H.A. Katus, P.W. Raake Source Type: research